This is a repository copy of *Competition between two high- and low-affinity protein-binding sites in myosin VI controls its cellular function*.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/153949/

Version: Accepted Version

**Article:**
Fili, N., Hari-Gupta, Y., Aston, B. et al. (6 more authors) (2019) Competition between two high- and low-affinity protein-binding sites in myosin VI controls its cellular function. Journal of Biological Chemistry. ISSN 0021-9258

https://doi.org/10.1074/jbc.ra119.010142

This research was originally published in the Journal of Biological Chemistry. Natalia Fili, Yukti Hari-Gupta, Bjork Aston, Ália dos Santos, Rosemarie E Gough, Bana Alamad, Lin Wang, Marisa L. Martin-Fernandez and Christopher P. Toseland. Competition between two high- and low-affinity protein-binding sites in myosin VI controls its cellular function. Journal of Biological Chemistry 2019 © the Author(s).

**Reuse**
Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
Competition between two high- and low-affinity protein-binding sites in myosin VI controls its cellular function.

Natalia Fili#1, Yukti Hari-Gupta#2, Bjork Aston2, Ália dos Santos1, Rosemarie E Gough1, Bana Alamad2, Lin Wang3, Marisa L. Martin-Fernandez3 and Christopher P. Toseland1*
1Sheffield Cancer Centre, Department of Oncology and Metabolism, University of Sheffield, Sheffield, S10 2RX, UK
2School of Biosciences, University of Kent, Canterbury, UK.
3Central Laser Facility, Research Complex at Harwell, Science and Technology Facilities Council, Rutherford Appleton Laboratory, Harwell, Didcot, Oxford OX11 0QX, UK
#Equal contribution

Running Title: Binding partner regulation of myosin VI

*Corresponding Author: Sheffield Cancer Centre, Department of Oncology and Metabolism, University of Sheffield, Sheffield, S10 2RX, UK
c.toseland@sheffield.ac.uk

Key Words: myosin VI, disabled homolog 2 (DAB2), nuclear dot protein 52 (NDP52), estrogen receptor, transcription, tumor suppressor, protein-protein interaction, differentially expressed in ovarian carcinoma 2 (DOC-2), molecular motor

ABSTRACT
Myosin VI is involved in many cellular processes ranging from endocytosis to transcription. This multifunctional potential is achieved through alternative isoform splicing and through interactions of myosin VI with a diverse network of binding partners. However, the interplay between these two modes of regulation remains unexplored. To this end, we compared two different binding partners and their interactions with myosin VI by exploring the kinetic properties of recombinant proteins and their distribution in mammalian cells using fluorescence imaging. We found that selectivity for these binding partners is achieved through a high-affinity and a low-affinity motif within myosin VI. These two motifs allowed competition among partners for myosin VI. Exploring how this competition affects the activity of nuclear myosin VI, we demonstrate the impact of a concentration-driven interaction with the low-affinity binding partner DAB2, finding that this interaction blocks the ability of nuclear myosin VI to bind DNA and its transcriptional activity in vitro. We conclude that loss of DAB2, a tumor suppressor, may enhance myosin VI-mediated transcription. We propose that the frequent loss of specific myosin VI partner proteins during the onset of cancer leads to a higher level of nuclear myosin VI activity.

INTRODUCTION
Myosin VI (MVI) is an actin-based molecular motor which performs numerous vital roles in key cellular processes such as cell migration, endocytosis, exocytosis and transcription [1-3]. Defects in MVI lead to various diseases including hypertrophic cardiomyopathy, deafness and cancer [4-7]. MVI consists of the highly conserved actin-binding motor domain, a neck region and a C-terminal globular cargo binding domain (CBD) (Figure 1a). We have recently shown that MVI
can adopt a back-folded conformation, in which the CBD is brought in close proximity to the motor domain (Figure 1b) [3]. Moreover, two regions within the tail (MVI$_{TAIL}$, aa 814-1253) can be alternatively spliced, resulting in a 31 residue insertion (large-insert, LI) adjacent to the CBD, and/or an 9 residue insertion in the middle of the CBD (small-insert, SI) [8]. This leads to several splice isoforms, namely the non-insert (NI), SI, LI and LI+SI, each with distinct intracellular distributions and functions [8][9]. For example, the NI isoform is able to enter the nucleus, whereas the LI is confined to the cell periphery [3].

The intracellular localisation and function of MVI is also regulated through its interaction with a broad range of binding partners, such as disabled-2 (DAB2), the GAIP-interacting protein C-terminus (GIPC) and the nuclear dot protein 52 (NDP52). These partners specifically bind to one of two established motifs within the CBD of MVI, namely the RRL and WWY [10-12].

NDP52, also known as CALCOCO2, is an RRL binding partner of MVI. It was initially identified in the nucleus [13], but it was later found to be mostly cytoplasmic [14], with roles in cell adhesion and autophagy [10][15]. NDP52 has been shown to release the back-folded conformation of MVI, allowing MVI to dimerize and to interact with DNA, both of which enable coupling of MVI to RNA Polymerase II. Moreover, NDP52 has been shown to have a role in regulating transcription [3], possibly as a co-activator, similarly to its highly conserved family member CoCoA [16].

DAB2, also known as Differentially expressed in Ovarian Carcinoma (DOC-2), links MVI to clathrin-coated vesicles at the early stages of endocytosis [12], through interaction with the WWY motif. DAB2 is down-regulated in majority of breast and ovarian cancers. Moreover, depletion and re-expression of DAB2 can trigger tumorigenesis or suppress growth, respectively [17]. Therefore, DAB2 is considered as a tumour suppressor.

The selectivity of MVI for its binding partners is, in part, regulated by isoform splicing. The LI encodes an alpha helix which sits upon, and therefore blocks, the RRL motif [18]. This prevents partners, such as NDP52, interacting with the protein, and therefore the binding partner interactions of this isoform are driven by the WWY motif. In contrast, in the NI isoform, both the RRL and WWY motifs are available for binding. In this case, binding partner selectivity would be an important regulatory mechanism. In the light of our recent work on the regulation of the NI isoform by NDP52 [3] and with the aim to unravel such a regulatory the mechanism, we have established how competition between the two binding sites is achieved and how this can impact upon the role of nuclear MVI in gene expression.

RESULTS

Interactions between binding partners and myosin VI

In order to establish how the selectivity of MVI for its binding partners is regulated, we compared its interactions with two binding partners, namely NDP52 and DAB2, as representatives of RRL and WWY binding proteins, respectively. Given our recent work on the interaction of the NI isoform with NDP52 [3], here we focus on the interaction with DAB2.

Before investigating the effect of DAB2 upon MVI, we first assessed their interaction. Recombinant full length DAB2 was highly unstable and unable to yield sufficient amounts of protein for biochemical characterisation.
Therefore, we used the stable C-Terminal region of the protein (residues 649-770), which contains the MVI binding site [12]. This truncation of DAB2 will be referred to as tDAB2 throughout the manuscript, unless stated. To characterise the interaction between MVI and tDAB2, we performed an in vitro FRET assay by titrating Alexa555-MVI\textsubscript{TAIL(NI)} or Alexa555-MVI\textsubscript{TAIL(LI)} against FITC-DAB2. As demonstrated by the binding curves in Figures 1c and 1d, tDAB2 displayed relatively weak binding to the MVI\textsubscript{TAIL(NI)} (K\textsubscript{d} 11.6 \mu M). Binding was noticeably enhanced for the MVI\textsubscript{TAIL(LI)} (K\textsubscript{d} 3.5 \mu M), suggesting that the LI stabilises the interaction with tDAB2. For comparison, measurements were also performed with NDP52. Consistent with the previous results [3], MVI\textsubscript{TAIL(NI)} bound to NDP52 with a low micromolar affinity (K\textsubscript{d} 2.1 \mu M). In contrast, binding to the MVI\textsubscript{TAIL(LI)} was over 8-fold weaker (K\textsubscript{d} 17.3 \mu M), indicating that NDP52 selectively interacts with MVI\textsubscript{TAIL(NI)}, rather than the MVI\textsubscript{TAIL(LI)}. Based on this data, the differential affinity between the WWY and RRL sites suggests that the NI isoform would selectively bind RRL binding partners over its WWY competitors. In contrast, the LI isoform shows preferential binding to the WWY partners because the LI helix (i) masks the higher affinity RRL motif [18], thereby impeding NDP52 binding, and (ii) may provide additional interaction sites to increase the DAB2 affinity. To further explore these interactions with full length proteins, we assessed their association within cells. In HeLa cells, which only express the NI isoform [19], endogenous MVI shows little co-localisation with endogenous DAB2, if any (Figure 2a). In contrast, transiently expressed GFP-LI showed significant co-localisation with endogenous DAB2, as highlighted by the 10-fold increase in Pearson’s coefficient (Figure 2b and 2d). Consistent with the titration measurements, these observations support that the selectivity of MVI for its partners differs depending on the isoform. Our biochemical data suggested that the association of MVI with its partners is a concentration dependent process. To address this in the cellular environment, we artificially increased the intracellular levels of the NI isoform by transient overexpression of GFP-NI-MVI and assessed its colocalization with endogenous DAB2. Consistent with our titration data, increase in the NI intracellular levels shifted the extent of colocalization between the two proteins at levels comparable to the LI-MVI (Figure 2b and 2d). To confirm the specificity of this observation, we also assessed the effect of transiently over-expressing two mutants of the NI isoform, each carrying mutations that abolish one of the two binding motifs (Figure 2c and 2d). As expected, the GFP-NI-MVI (WWY/WLY), in which the WWY binding site is abolished, did not show any colocalization with DAB2. In contrast, mutation of the RRL motif did not affect the colocalization with DAB2. In fact, there was a slight increase in colocalization, which may relate to an increase in free MVI available to interact with WWY binding partners. Overall, these observations are consistent with the conclusions from the titration measurements which suggest that significant interactions between the NI MVI\textsubscript{TAIL} and tDAB2 can occur at higher protein concentrations. Therefore, our data support that the WWY binding site has a weaker affinity for protein-protein interactions.

DAB2 mediates Myosin VI Large Insert isoform dimerization

We have previously revealed how NDP52 interacts with MVI NI to bring about its unfolding [3]. Unfolding subsequently exposes dimerization
sites, leading to protein oligomerization. However, the ability of the LI isoform to dimerise has not been yet explored. The presence of the additional alpha helix in this isoform may perturb its dimerization. To test if DAB2 can oligomerize both isoforms, we performed a FRET assay, whereby two pools of MVIT_{TAIL(NI)} or MVIT_{TAIL(LI)} were labelled, one with FITC and the other one with Alexa555. Titrations revealed a weak association between the two tail pools (Figures 3a and 3b), consistent with our previous results [3]. Upon addition of 20 μM excess tDAB2, a change in FRET signal was observed, indicating the formation of a dimer complex. This occurred with both the NI and LI tails, with the LI signal being higher possibly due the higher association with tDAB2. 20 μM excess of NDP52 was able to trigger dimerization of MVIT_{TAIL(NI)} but failed to significantly dimerize the MVIT_{TAIL(LI)}, consistent with the poor binding of NDP52 to the LI isoform. 20 μM excess of NDP52 was able to trigger dimerization of MVIT_{TAIL(NI)} but failed to significantly dimerize the MVIT_{TAIL(LI)}, consistent with the poor binding of NDP52 to the LI isoform. 20 μM excess of NDP52 was able to trigger dimerization of MVIT_{TAIL(NI)} but failed to significantly dimerize the MVIT_{TAIL(LI)}, consistent with the poor binding of NDP52 to the LI isoform. Upon addition of 20 μM excess tDAB2, a change in FRET signal was observed, indicating the formation of a dimer complex. This occurred with both the NI and LI tails, with the LI signal being higher possibly due the higher association with tDAB2. 20 μM excess of NDP52 was able to trigger dimerization of MVIT_{TAIL(NI)} but failed to significantly dimerize the MVIT_{TAIL(LI)}, consistent with the poor binding of NDP52 to the LI isoform.

Taking all our data together, we propose the following model: NDP52 specifically associates with MVI-NI through the RRL motif to trigger unfolding of the protein and subsequent dimerization. Similarly, binding of DAB2 to the LI isoform through the WWY motif also leads to dimerisation. Whilst DAB2 has also the ability to bind the NI isoform, its weaker affinity for the WWY motif makes this interaction less favourable compared to the high affinity binding of NDP52 to the RRL motif. In this way, the unfolding and dimerization of the NI isoform is preferentially assigned to the RRL binding partners.

**Effect of binding partner competition upon the biochemical properties of nuclear myosin VI**

We have shown that association of a binding partner with either the RRL or the WWY motif can bring about dimerization. We have also shown that the selectivity of MVI for its binding partners is regulated by the differential affinity between the two motifs. However, what is the biological impact of this binding partner selectivity and what would be the effect if its gets disrupted? More specifically, what is the effect of DAB2 upon the function of nuclear MVI, which we previously identified as the NI isoform? We have established that DAB2 can interact with this isoform at high protein concentrations. Interestingly, DAB2 can also be detected in the nucleus (Figure 4a) and therefore it could interact with nuclear MVI.

We have previously shown that MVI contains a DNA binding site on two conserved loops in the CBD (Supplementary Figure 1a) [3]. These sites are only exposed upon unfolding of the tail domain and therefore, DNA binding is dependent upon the interaction with a binding partner [3]. First, we wanted to assess the effect of binding partners upon the ability of MVI to bind DNA, which is critical for its role in transcription [3]. To determine DNA binding, we measured the fluorescence anisotropy of labelled DNA. As reported previously [3], NDP52 independently binds to DNA itself and therefore, it is unsuitable for this purpose. In contrast, tDAB2 does not bind DNA (Supplementary Figure 1b) and therefore it can be used to determine its impact upon MVI binding DNA. To this end, we monitored the binding of MVI CBD to fluorescently labelled DNA (Figure 4b). Whereas the CBD alone could bind to DNA with strong affinity (K_a 140 nM), the presence of DAB2 inhibited DNA binding in a concentration-dependent manner. Interestingly, the DNA binding sites of MVI are in close proximity to the WWY motif where DAB2 binds (Supplementary Figure 1a). Therefore, the interaction of DAB2 with MVI might induce a steric hindrance, or a
structural change within the CBD, which prevents the complex from binding DNA.

The ability of MVI to bind DNA is important for efficient in vitro transcription (Fili et al). Therefore, to assess the effect of DAB2 on the transcription activity of MVI, we performed in vitro transcription assays using the HeLaScribe nuclear extracts (Figure 4c). Antibody-depletion of MVI leads to a 70 % decrease in transcription yield. A similar impact is achieved through the addition of recombinant CBD to displace MVI. Interestingly, addition of 10 μM recombinant tDAB2 leads to a 60 % decrease in transcription. We therefore propose that this effect is due to tDAB2 interfering with the DNA binding ability of MVI in the HeLaScribe lysate. This effect was observed in a concentration-dependent manner, consistent with our anisotropy data. The addition of 10 μM NDP52 did not decrease the transcription yield suggesting that the tDAB2 effect is not due to sequestering MVI through binding to the protein. Moreover, no further decrease in transcription yield was found when tDAB2 was added following antibody-depleted of MVI.

The compromised transcription activity that we observed following antibody-depletion of MVI can be partially rescued through the addition of recombinant MVI (Figure 4d). Addition of recombinant MVI and NDP52 together can restore transcription to about 60% (Figure 4d), possibly due to the unfolding and dimerization of the protein. However, addition of recombinant MVI and tDAB2 together failed to rescue the transcription yield, reinforcing that the observed effect is specific to DAB2, possibly through its interference with DNA binding. Taken together, our data suggest that DAB2 is a negative regulator of the transcription activity of MVI.

Effect of binding partner competition upon the nuclear functions of myosin VI

We have shown how two different binding partners can have contrasting effects on the biochemical properties and activity of MVI in vitro. On this basis, we then wanted to explore the impact of different binding partners on the cellular function of MVI, and in particular its nuclear role in breast cancer cell line MCF-7. MVI is also distributed throughout the cell body, including the nucleus (Figure 5a). In these cells, MVI has been already shown to be required for the expression of genes responsive to estrogen receptor (ER) signalling. When MCF-7 cells underwent siRNA knockdown of MVI, or treatment with TIP, the small molecule inhibitor of MVI, there was a decrease in the expression of estrogen-activated PS2 and GREB1 (Figure 5b). The impact of both treatments was similar, with a decrease of 70-80% for PS2 and 30-40% for GREB1. Inhibition of MVI with TIP has already been shown to decrease the transcription yield in vitro (20). Based on our data, we can now suggest the motor activity of MVI is required for ER signalling.

The genes that are under the control of the estrogen receptor relate, amongst others, to cell growth. Given the role of MVI in the expression of these genes, we then assessed the effect of MVI knockdown on MCF-7 growth (Figure 5c). Indeed, the loss of MVI attenuates cell growth, which suggests there is a correlation between the role in gene expression and overall cell growth.

MCF-7 cells, along with many other estrogen receptor positive breast and ovarian cancer cell lines, have lost or attenuated DAB2 expression (Supplementary Figure 2a). Moreover, the reintroduction of DAB2 to these cell lines has been suggested to suppress tumourgenicity (17). Based upon the
impact of MVI on the ER driven gene expression and our in vitro data demonstrating the impact of DAB2 upon MVI associated transcription, we wished to explore whether reintroduction of DAB2 in MCF-7 could lead to a perturbation of in the expression of ER target genes. To this end, we transiently expressed full length DAB2-mRFP in MCF-7 cells (Supplementary Figure 2a and b) and then monitored the expression of PS2 and GREB1. Interestingly, the presence of DAB2 in MCF-7 resulted in a 20-30% decrease in the expression of these ER-target genes.

To confirm that this decrease is due to the targeting of MVI, we transiently expressed in MCF-7 two truncations of DAB2 (Supplementary Figure 2c): the DAB2<sub>649-770</sub> region which contains the MVI binding site and is the one used in our biochemical assays, and the DAB2<sub>1-648</sub> which cannot associate with MVI [12]. As expected, the DAB2<sub>649-770</sub> resulted in a 40-50% decrease in the expression of the two ER target genes, whereas the DAB2<sub>1-648</sub> did not have any effect, confirming that the observed decrease in gene expression is indeed due to the interaction of DAB2 with MVI. Overall, our observations suggest that DAB2 can function in the cell as a negative regulator of MVI in the expression of ER-target genes.

**DISCUSSION**

The structural regulation of MVI seems to follow a single general mechanism, which is summarised by the following model: MVI exists as a folded monomer which interacts with binding partners through the CBD. These interactions lead to MVI unfolding, and subsequent dimerization of the protein through its tail domain. As shown previously, this generates a processive motor protein [5].

Moreover, here we have shown that this widely applied mechanism of structural regulation is under the control of a finely tuned interplay between binding partners and the MVI isoforms. In the case of the LI isoform, structural studies have revealed how the RRL motif is blocked by the LI helix [18], allowing only the WWY partners, such as DAB2, to bind to MVI. We have confirmed this here biochemically, by measuring the binding partner interactions at each site, using DAB2 as a representative example. In contrast, the NI isoform, in which both the RRL and WWY motif are readily accessible, should be able associate with any partner. We have therefore explored the mechanism underlying the partner selectivity in this case. We have revealed that the NI isoform can enact selectivity through the differential affinity between the two sites, with the RRL motif having stronger binding affinity over the WWY. In this way, the selectivity for binding partners is based upon the relative concentration of WWY versus RRL partners. While the overall cellular concentrations of DAB2 is unlikely to be in the micromolar range. However, it is possible for there to be local high protein concentrations which can generate micromolar concentrations within a defined volume. In these instances interactions between MVI and binding partners would be observed. Moreover, cellular interactions may be supported by additional protein/cargo factors thereby
increasing the affinity. There could also be a global change in protein expression levels. For instance, the loss of a WWY partner would perturb the dynamics leading to an enhanced role of RRL binding partners.

This mechanism of selectivity is particularly relevant for the regulation of nuclear MVI, which is the NI isoform [3]. Here, we have demonstrated the impact of a concentration driven interaction with the low affinity binding partner DAB2. Indeed, interaction with DAB2 blocked the ability of MVI to bind DNA and subsequently its transcription activity in vitro.

The impact of DAB2 on the biochemical properties of MVI raised questions about its impact on the cellular functions of MVI. DAB2 has been proposed to function as a tumour suppressor however, the underlying mechanism remains elusive. Here, we have proposed that at least part of this activity could relate to the down-regulation of nuclear MVI in transcription. As nuclear MVI is linked to estrogen receptor gene expression, this would in turn attenuate the activity of the estrogen receptor, subsequently leading to a decrease in tumorigenicity. Conversely, loss of a DAB2 would perturb the dynamics leading to an enhanced role of RRL binding partners, like NDP52 leading to enhanced MVI transcription activity. Cancer cell lines, such as the MCF-7, over-express the NI isoform of MVI, which is the one able to translocate to the nucleus, and they are therefore primed for transcriptional activity. This is further enhanced in MCF-7 cells by the loss of DAB2 expression, which relieves the DAB2-mediated negative regulation. Overall, this would lead to a high level of ER activity, which is MVI-dependent. Interestingly, reintroduction of DAB2 in these cells has an effect on their tumorigenic potential [17]. In this study, we have confirmed that reintroduction of DAB2 perturbs the transcription landscape downstream the ER and revealed this is due to MVI targeting. We therefore suggest that the down-regulation of the transcriptional activity of MVI is indeed part of the role of DAB2 as a tumour suppressor.

In summary, this study has allowed us to gain new insights into the regulation of MVI. The mechanism of selectivity of binding partners is isoform depended. While the LI MVI employs a structural selection for its binding partners, the selectivity of the NI isoform is regulated by the relative expression levels of the partners. Finally, we provide an example of how the intracellular levels of MVI binding partners can modulate the cellular function of the protein. We propose that the tumour suppressor activity of DAB2 is, in part, related to the down-regulation of estrogen receptor target gene activation by nuclear MVI. These insights open new avenues for exploring how the activity of this multifunctional motor protein is regulated within the nucleus and the cytoplasm, as well.

**METHODS**

Constructs

A list of constructs and PCR primers are provided in Supplementary Table 1 and 2, respectively. Constructs generated in this work are described below: The following human full-length Myosin VI mutants (EGFP-C3-NI-MVI-RRL-AAA and EGFP-C3-NI-MVI-WWY-WLY) were a kind gift from F. Buss (CIMR). The full length human DAB2-mRFP was isolated by PCR from pET28a-DAB2-RFP plasmid, restriction digested with NheI and NotI and cloned into the pZsgreen1-N1 backbone following removal of Zsgreen1. The
human DAB2 truncations were generated by PCR isolation of the DAB2 fragment containing the Myosin VI binding site (aa 649-770) and the rest of DAB2 (aa 1-648) which does not contain the Myosin VI binding site from the above DAB2-mRFP plasmid. The PCRs were restriction digested by XhoI and SacII and cloned into pEGFP-C3.

**Protein expression and purification in Escherichia coli**
Recombinant constructs were expressed in E.coli BL21 DE3 cells (Invitrogen) in Luria Bertani media. Proteins were purified by affinity chromatography (HisTrap FF, GE Healthcare). The purest fractions were further purified through a Superdex 200 16/600 column (GE Healthcare).

**Protein Expression using Baculovirus system**
Full-length myosin VI NI and LI and Xenopus calmodulin were expressed in Sf9 and Sf21 (Spodoptera frugiperda) insect cells using the Baculovirus expression system. Sf9 cells were cultured in suspension in sf900 media (Gibco) at 27°C to generate the P1-3 recombinant baculovirus stocks. Finally, expression of recombinant proteins was set up by infecting sf21 cells with the P3 viral stock in ExCell 420 media (Sigma). The cells were harvested by centrifugation (as above) for protein purification after 4 days. Prior to sonication, an additional 5 mg Calmodulin was added with 2 mM DTT. After sonication, 5 mM ATP and 10 mM MgCl₂ were added and the solution was rotated at 4°C for 30 min before centrifugation (20,000g, 4°C, 30 min). Then, the cell lysate was subjected to the purification steps described above.

**Protein labelling**
Proteins were transferred into 50 mM Na-phosphate (pH 6.5) using a PD10 desalting column. Samples were then incubated with a 5-fold excess of dye for 4 hours, rotating at 4°C. Excess dye was removed using a PD10 desalting column pre-equilibrated with 50 mM Na-Phosphate, 150 mM NaCl and 1 mM DTT. Labelling efficiency was calculated based on the absorbance at 280 nm and the absorbance maximum of the dye. Typical efficiency was 90%, whereby the less than complete labelling was taken as an indicator for a single dye per protein. This was tested for isolated preparations in mass spectroscopy, which revealed both an unlabelled and single labelled population.

**Cell culture and Transfection**
HeLa (ECACC 93021013) and MCF7 (ECACC 86012803) cells were cultured at 37°C and 5% CO₂, in Gibco MEM Alpha medium with GlutaMAX (no nucleosides), supplemented with 10% Fetal Bovine Serum (Gibco), 100 units/ml penicillin and 100 µg/ml streptomycin (Gibco). For the transient expression of MVI isoforms and mutants, full length DAB2 and truncations, HeLa cells and/or MCF7 cells grown on glass coverslips were transfected with EGFP-NI-MVI, EGFP-LI-MVI, EGFP-NI-MVI-RRR-Y, EGFP-NI-MVI-WFY-WLY, DAB2-mRFP, EGFP-DAB2-1-648 and EGFP-DAB2-649-770 constructs using Lipofectamine 2000 (Invitrogen), following the manufacturer’s instructions. Depending on the construct, 24 h - 72 h after transfection, cells were subjected to nuclear staining using Hoechst 33342 (Thermo Scientific), fixed and analysed or subjected to indirect immunofluorescence (see below). Full length DAB2-RFP cDNA was electroporated into MCF7 cells using BioRad Gene Pulser Xcell TM electroporation system. After trypsinization, harvested cells were washed with 1X PBS, counted and
1.5x10^6 cells were resuspended in 800ul of cold Opti-MEM media and the cell suspension was kept on ice. 10µg of DNA was added to the cell suspension and the mixture was transferred to the Biorad 4mm cuvette. The cells were then pulsed using exponential-decay protocol with a voltage of 300V and a capacitance of 350µF. Cells were allowed to recover for 5 minutes after which warm complete media (MEM) was added to them and they were plated in a 6 well plate at a density of 0.5x10^6 cells per well. The cells were collected for protein or RNA extraction after 48 hours.

**Immunofluorescence**

Transfected and non-transfected HeLa or MCF-7 cells were fixed for 15 min at room temperature in 4% (w/v) paraformaldehyde (PFA) and residual PFA was quenched for 15 min with 50 mM ammonium chloride. All subsequent steps were performed at room temperature. Cells were permeabilised and simultaneously blocked for 15 min with 0.1 % (v/v) Triton X-100 and 2 % (w/v) BSA in PBS. Cells were then immuno-stained against the endogenous proteins by 1 hour incubation with the indicated primary and subsequently the appropriate fluorophore-conjugated secondary antibody (details below), both diluted in 2% (w/v) BSA in PBS. The following antibodies were used at the indicated dilutions: Rabbit anti-MVI (1:200, Atlas-Sigma HPA0354863-100UL), Mouse anti-DAB2 (1:100, Abcam ab88590) ,donkey anti-mouse Alexa Fluor 488-conjugated (1:500, Abcam ab88590) ,donkey anti-mouse Alexa Fluor 555-conjugated (1:500, Abcam Ab150110), donkey anti-rabbit Alexa Fluor 488-conjugated antibody (1:500, Abcam Ab181346) and donkey anti-rabbit Alexa Fluor 555-conjugated antibody (1:500, Abcam Ab150074).

Coverslips were mounted on microscope slides with Mowiol (10% (w/v) Mowiol 4-88, 25% (w/v) glycerol, 0.2 M Tris-HCl, pH 8.5), supplemented with 2.5% (w/v) of the anti-fading reagent DABCO (Sigma).

For co-localisation analysis, 20 Fields of view were recorded with 2-4 cells per field. We ensured all cells were transfected within the field. Pearson’s coefficients were obtained with the JACoP plugin[21] for ImageJ.

**Immunoblot Analysis**

The total protein concentration was determined by Bradford Assay (Sigma) following the manufacturer’s instructions. Cell lysates were heat-denatured and resolved by SDS-PAGE. The membrane was probed against the endogenous proteins by incubation with mouse Anti-DAB2 polyclonal antibody (1:1000, Abcam ab88590) and subsequently a goat anti-mouse antibody coupled to horseradish peroxidase (1:15000, Abcamab97023). The bands were visualised using the ECL Western Blotting Detection Reagents (Invitrogen) and the images were taken using Syngene GBox system. Images were processed in ImageJ.

**Fluorescence Imaging**

Cells were visualised using either the ZEISS LSM 880 confocal microscope or the widefield Olympus IX71 microscope. The former was equipped with a Plan-Apochromat 63x 1.4 NA oil immersion lens (Carl Zeiss, 420782-9900-000). Three laser lines, i.e. 405 nm, 488 nm and 561 nm, were used to excite the fluorophores, i.e. Hoechst, GFP and RFP, respectively. The built-in dichroic mirrors (Carl Zeiss, MBS-405, MBS-488 and MBS-561) were used to reflect the excitation laser beams on to cell samples. The emission spectral bands for fluorescence collection were 410 nm-
524 nm (Hoechst), 493 nm-578 nm (GFP) and 564 nm-697 nm (RFP). The detectors consisted of two multi anode photomultiplier tubes (MA-PMT) and 1 gallium arsenide phosphide (GaAsP) detector. The green channel (GFP) was imaged using GaAsP detector, while the blue (Hoechst) and red (RFP) channels were imaged using MA-PMTs. ZEN software (Carl Zeiss, ZEN 2.3) was used to acquire and render the confocal images. The later was equipped with an PlanApo 100xOTIRFM-SP 1.49 NA lens mounted on a PIFOC z-axis focus drive (Physik Instrumente, Karlsruhe, Germany), and illuminated with an automated 300W Xenon light source (Sutter, Novato, CA) with appropriate filters (Chroma, Bellows Falls, VT). Images were acquired using a QuantEM (Photometrics) EMCCD camera, controlled by the Metamorph software (Molecular Devices). The whole volume of cells was imaged by acquiring images at z-steps of 200 nm. Widefield images were deconvolved with the Huygens Essential version 17.10 software. Confocal Images were deconvolved using the Zeiss Zen2.3 Blue software, using the regularised inverse filter method. All images were then analysed by ImageJ.

**DNA Substrates**

DNA substrate ds40 consisted of Labeled (TTAGTTGTTCGTAGTGCTCGTCTGGCTCTGGATTACCCGC*FAM) and unlabelled (GCGGGTAATCCAGAGCCAGACGAGCACTACGAACAACTAA) oligonucleotides purchased from IDT. To form duplex DNA substrates, oligonucleotides were mixed at equimolar concentrations at either 50 µM in water or a buffer containing 50 mM Tris.HCl at pH 7.5, 150 mM NaCl, and 3 mM MgCl2.

**In vitro transcription**

The DNA template was the pEGFP-C3 linearized plasmid containing the CMV promoter which would generate a 130-base run-off transcript. The HelaScribe (Promega) reactions were performed in triplicates, through two independent experiments, according to the manufacturer’s instructions. The reactions were performed for 60 min at 25°C. Reactions were also performed following pre-clearance with the MVI antibody. Protein G Dynabeads (Invitrogen) were prepared according to manufacturer’s instructions before being loaded with 4 µg antibody. Samples were incubated for 30 min on ice and beads were extracted immediately before performing the transcription reaction.

**RNA extraction and RT-qPCR**

RNA from DAB2-RFP transfected or non-transfected MCF7 cells was extracted using Gene Jet RNA purification kit (Thermo scientific) according to manufacturer’s protocol. The RNA concentration was measured using Geneflow Nanophotometer and RT-qPCR was performed with one-step QuantiFast SYBR Green qPCR kit (Qiagen) using 50ng of RNA in each sample. A list of qPCR primers is given in Supplementary Table 3.

**Incucyte**

Cells were seeded onto 96-well tissue culture dishes at equal densities in 6 replicates. After attachment over-night, cells were transfected with MVI siRNA. Photomicrographs were taken every hour using an IncuCyte live cell imager (Essen Biosciences, Ann Harbor, MI) and confluency of cultures was measured using IncuCyte software. Confluency values between wells were normalised to initial confluency for comparison.

**Incucyte**

Cells were seeded onto 96-well tissue culture dishes at equal densities in 6 replicates. After attachment over-night, cells were transfected with MVI siRNA. Photomicrographs were taken every hour using an IncuCyte live cell imager (Essen Biosciences, Ann Harbor, MI) and confluency of cultures was measured using IncuCyte software. Confluency values between wells were normalised to initial confluency for comparison.
For quantification, mRNA was purified using Gene Jet RNA purification kit (Thermo scientific) according to manufacturer’s protocol and RT-qPCR was performed with one-step QuantiFast SYBR Green qPCR kit (Qiagen).

**Titration measurements**

All reactions were performed at 25 °C in a buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM sodium chloride and 1 mM DTT in a final volume of 100 µL. Measurements were performed using a ClarioStar Plate Reader (BMG Labtech).

Intensity measurements were performed at the following wavelengths: FITC (ex. 490nm), Alexa Fluor 555 (ex. 555nm). FITC to Alexa Fluor 555 FRET measurements were performed using the following wavelengths ex. 470nm and em. 575nm. Anisotropy was measured with the instrument in the T format, allowing simultaneous acquisition of parallel (I//) and perpendicular (I\perp) components using BMG filter-sets for fluorescein (Ex. 482/16-10, Dichroic LP504 and em. 530/-40).

**Analysis of kinetic data**

For Fluorescence Anisotropy titrations: Anisotropy was calculated, as described below, based upon established procedures [22], [23-25].

Total fluorescence intensity (F\textsubscript{t}) is given by:

\[
F_t = \sum c_i F_i
\]

Total anisotropy (A\textsubscript{t}) is given by:

\[
A_t = \frac{\sum c_i F_i A_i}{F_t}
\]

Where \(c_i\) is the concentration of species \(i\), \(F_i\) is the fluorescence intensity per unit of concentration and \(A_i\) is the anisotropy. This is calculated from the parallel and perpendicular fluorescence intensity (I) in relation to the plane of excitation by:

\[
A_i = \frac{I_{\parallel} - I_{\perp}}{I_{\parallel} + 2I_{\perp}}
\]

As anisotropy is additive for multiple fluorescence species in solution, it is used to give a measure of their relative concentrations. For MVI (and various constructs) there are two fluorescence species, DNA and MVI.DNA. The total anisotropy can then be calculated in terms of the dissociation constant (K\textsubscript{d}) for the MVI.DNA complex:

\[
A_t = \frac{\ADNA([DNA]_t - [MVI.DNA]) + \AMVIdnaQ[MVI.DNA]}{[DNA]_t - [MVI.DNA] + Q[MVI.DNA]}
\]

Where

\[
[MVI.DNA] = \frac{([MVI]_t + [DNA]_t + K_d) - \sqrt{([MVI]_t + [DNA]_t + K_d)^2 - 4[MVI]_t[DNA]_t}}{2}
\]

And where [MVI]\_t and [DNA]\_t are the total concentrations for each reactant. [MVI.DNA] is the concentration of the protein-bound DNA complex. Q is the fluorescence intensity of MVI.DNA relative to DNA. The anisotropy data were fitted to obtain dissociation constants based on the above equations using GraFit fitting software (Leatherbarrow, R. J. (2001) Grafit Version 5, Erithacus Software Ltd., Horley, U.K.).

For the FRET titrations: The 575 nm intensity data was corrected for the increase in intensity due to a small direct excitation. This background signal was subtracted from the dataset to leave the FRET values. The titration curves for the MVI\_TAIL interactions were fitting to a binding quadratic equation:

\[
\frac{[\text{Complex}]}{([\text{FITC}] + [\text{AP555}] + K_d) - \sqrt{([\text{FITC}] + [\text{AP555}] + K_d)^2 - 4[\text{FITC}][\text{AP555}]}}
\]

**Data Availability**

The data supporting the findings of this study are available from the corresponding author on request.
ACKNOWLEDGEMENTS
We thank the MRC (MR/M020606/1) and STFC (19130001) for funding. We also thank Darren Griffin for sharing of equipment.

Competing financial interests: The authors declare no competing financial interests.

REFERENCES
1. Roberts, R., Lister, I., Schmitz, S., Walker, M., Veigel, C., Trinick, J., Buss, F., and Kendrick-Jones, J. (2004) Myosin VI: cellular functions and motor properties. Philosophical transactions of the Royal Society of London. Series B, Biological sciences 359, 1931-1944
2. Vreugde, S., Ferrai, C., Miluzio, A., Hauben, E., Marchisio, P. C., Crippa, M. P., Bussi, M., and Biffo, S. (2006) Nuclear myosin VI enhances RNA polymerase II-dependent transcription. Molecular cell 23, 749-755
3. Fili, N., Hari-Gupta, Y., Dos Santos, A., Cook, A., Poland, S., Ameer-Beg, S. M., Parsons, M., and Toseland, C. P. (2017) NDP52 activates nuclear myosin VI to enhance RNA polymerase II transcription. Nat Commun 8, 1871
4. Avraham, K. B., Hasson, T., Steel, K. P., Kingsley, D. M., Russell, L. B., Mooseker, M. S., Copeland, N. G., and Jenkins, N. A. (1995) The mouse Snell's waltzer deafness gene encodes an unconventional myosin required for structural integrity of inner ear hair cells. Nature genetics 11, 369-375
5. Dunn, T. A., Chen, S., Faith, D. A., Hicks, J. L., Platz, E. A., Chen, Y., Ewing, C. M., Sauvageot, J., Isaacs, W. B., De Marzo, A. M., and Luo, J. (2006) A novel role of myosin VI in human prostate cancer. The American journal of pathology 169, 1843-1854
6. Mohiddin, S. A., Ahmed, Z. M., Griffith, A. J., Tripodi, D., Friedman, T. B., Fananapazir, L., and Morell, R. J. (2004) Novel association of hypertrophic cardiomyopathy, sensorineural deafness, and a mutation in unconventional myosin VI (MYO6). Journal of medical genetics 41, 309-314
7. Yoshida, H., Cheng, W., Hung, J., Montell, D., Geisbrecht, E., Rosen, D., Liu, J., and Naora, H. (2004) Lessons from border cell migration in the Drosophila ovary: A role for myosin VI in dissemination of human ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America 101, 8144-8149
8. Buss, F., Arden, S. D., Lindsay, M., Luzio, J. P., and Kendrick-Jones, J. (2001) Myosin VI isoform localized to clathrin-coated vesicles with a role in clathrin-mediated endocytosis. The EMBO journal 20, 3676-3684
9. Au, J. S., Puri, C., Ihrke, G., Kendrick-Jones, J., and Buss, F. (2007) Myosin VI is required for sorting of AP-1B-dependent cargo to the basolateral domain in polarized MDCK cells. The Journal of cell biology 177, 103-114
10. Morriswood, B., Ryzhakov, G., Puri, C., Arden, S. D., Roberts, R., Dendrou, C., Kendrick-Jones, J., and Buss, F. (2007) T6BP and NDP52 are myosin VI binding partners with potential roles in cytokine signalling and cell adhesion. Journal of cell science 120, 2574-2585
11. Naccache, S. N., Hasson, T., and Horowitz, A. (2006) Binding of internalized receptors to the PDZ domain of GIPC/synectin recruits myosin VI to endocytic vesicles. Proceedings of the National Academy of Sciences of the United States of America 103, 12735-12740
12. Spudich, G., Chibalina, M. V., Au, J. S., Arden, S. D., Buss, F., and Kendrick-Jones, J. (2007) Myosin VI targeting to clathrin-coated structures and dimerization is mediated by binding to Disabled-2 and PtdIns(4,5)P2. Nature cell biology 9, 176-183
13. Korioth, F., Gieffers, C., Maul, G. G., and Frey, J. (1995) Molecular characterization of NDP52, a novel protein of the nuclear domain 10, which is redistributed upon virus infection and interferon treatment. The Journal of cell biology 130, 1-13
14. Sternsdorf, T., Jensen, K., Zuchner, D., and Will, H. (1997) Celluar localization, expression, and structure of the nuclear dot protein 52. The Journal of cell biology 138, 435-448
15. Mostowy, S., Sancho-Shimizu, V., Hamon, M. A., Simeone, R., Brosch, R., Johansen, T., and Cossart, P. (2011) p62 and NDP52 proteins target intracytosolic Shigella and Listeria to different autophagy pathways. *The Journal of biological chemistry* **286**, 26987-26995

16. Yang, C. K., Kim, J. H., and Stallcup, M. R. (2006) Role of the N-terminal activation domain of the coiled-coil coactivator in mediating transcriptional activation by beta-catenin. *Molecular endocrinology* **20**, 3251-3262

17. He, J., Smith, E. R., and Xu, X. X. (2001) Disabled-2 exerts its tumor suppressor activity by uncoupling c-Fos expression and MAP kinase activation. *The Journal of biological chemistry* **276**, 26814-26818

18. Wollscheid, H. P., Biancospino, M., He, F., Magistrati, E., Molteni, E., Lupia, M., Soffientini, P., Rottner, K., Cavallaro, U., Pozzoli, U., Mapelli, M., Walters, K. J., and Polo, S. (2016) Diverse functions of myosin VI elucidated by an isoform-specific alpha-helix domain. *Nature structural & molecular biology* **23**, 300-308

19. Puri, C., Chibalina, M. V., Arden, S. D., Kruppa, A. J., Kendrick-Jones, J., and Buss, F. (2010) Overexpression of myosin VI in prostate cancer cells enhances PSA and VEGF secretion, but has no effect on endocytosis. *Oncogene* **29**, 188-200

20. Cook, A., Hari-Gupta, Y., and Toseland, C. P. (2018) Application of the SSB biosensor to study in vitro transcription. *Biochemical and biophysical research communications* **496**, 820-825

21. Bolte, S., and Cordelieres, F. P. (2006) A guided tour into subcellular colocalization analysis in light microscopy. *Journal of microscopy* **224**, 213-232

22. Brownbridge, G. G., Lowe, P. N., Moore, K. J., Skinner, R. H., and Webb, M. R. (1993) Interaction of GTPase activating proteins (GAPs) with p21ras measured by a novel fluorescence anisotropy method. Essential role of Arg-903 of GAP in activation of GTP hydrolysis on p21ras. *The Journal of biological chemistry* **268**, 10914-10919

23. Soh, Y. M., Burmann, F., Shin, H. C., Oda, T., Jin, K. S., Toseland, C. P., Kim, C., Lee, H., Kim, S. J., Kong, M. S., Durand-Diebold, M. L., Kim, Y. G., Kim, H. M., Lee, N. K., Sato, M., Oh, B. H., and Gruber, S. (2015) Molecular basis for SMC rod formation and its dissolution upon DNA binding. *Molecular cell* **57**, 290-303

24. Toseland, C. P. (2014) Fluorescence to study the ATPase mechanism of motor proteins. *Exs* **105**, 67-86

25. Toseland, C. P., and Geeves, M. A. (2014) Rapid reaction kinetic techniques. *Exs* **105**, 49-65

26. Postma, M., and Goedhart, J. (2019) PlotsOfData-A web app for visualizing data together with their summaries. *Plos biology* **17**, e3000202

27. Yu, C., Feng, W., Wei, Z., Miyanoiri, Y., Wen, W., Zhao, Y., and Zhang, M. (2009) Myosin VI undergoes cargo-mediated dimerization. *Cell* **138**, 537-548
Figure 1 Interaction between Myosin VI and binding partners NDP52 and DAB2.
(a) Cartoon depiction of the key regions of the MVI\textsubscript{TAIL}, as discussed in the text. This highlights position of the large insert, along with NDP52 and DAB2 binding sites.
(b) Cartoon depiction of MVI backfolding with contacts between the CBD and motor, as described in (3).
(c) FRET titration of MVI\textsubscript{TAIL(NI)} against 1 \textmu M NDP52 (red triangles) or tDAB2 (blue squares).
(d) FRET titration of MVI\textsubscript{TAIL(LI)} against 1 \textmu M NDP52 (red triangles) or tDAB2 (blue squares).
All titration data fitting was performed as described in Methods giving a \( K_d \) as plotted (Error bars represent SEM from three independent experiments).
Figure 2
Figure 2 Myosin VI interaction with DAB2 in HeLa cells.
(a) Immunofluorescence staining against MVI (green) and DAB2 (magenta) in HeLa cells. White foci depict colocalization.
(b) Representative images of transiently expressed NI- and LI-GFP-MVI in HeLa cells combined with immunofluorescence staining against DAB2.
(c) Representative images of transiently expressed NI-MVI mutants WWY/WLY and RRL/AAA in HeLa cells combined with immunofluorescence staining against DAB2. Scale bar 10 μm in all images.
(d) Pearson’s coefficient for MVI colocalisation with DAB2 from images in a-c. Figure was generated using [26]. Each data point represents a field of view consisting of 2-4 cells. *** represents a p<0.001 by two-tailed t-test.
Figure 3 Binding partner driven dimerization of myosin VI.

(a) FRET titration of AF555-MVI_{TAIL(NI)} against 1 μM FITC-MVI_{TAIL(NI)} +/- tDAB2 (20 μM) and NDP52 (20 μM). Data fitting generated NDP52 $K_{dDIMER}$ as 4.3 μM and tDAB2 $K_{dDIMER}$ as 5.3 μM.

(b) FRET titration of AF555-MVI_{TAIL(LI)} against 1 μM FITC-MVI_{TAIL(LI)} +/- tDAB2 (20 μM) and NDP52 (20 μM). Data fitting generated NDP52 $K_{dDIMER}$ as 9.3 μM and tDAB2 $K_{dDIMER}$ as 3.3 μM.

All titration data fitting was performed as described in Methods (Error bars represent SEM from three independent experiments).
Figure 4 DAB2 represses the in vitro activity of nuclear myosin VI.
(a) Immunofluorescence staining against DAB2 (magenta) combined with DNA staining (Cyan) in HeLa cells. Scale bar 10 μm in all images.
(b) Fluorescence anisotropy titrations of the CBD against a 40 bp fluorescein amidite (FAM)-DNA (50 nM) with the highlighted concentrations of tDAB2. Data fitting was performed as described in Methods (K_d +/- SEM n = 3 independent experiments).
(c) In vitro transcription by HelaScribe extracts following antibody depletion as described in Methods, or in the presence of CBD at 25 μM, tDAB2 at 1 or 10 μM and NDP52 at 10 μM. Samples were normalized to a non-depleted control reaction. *** represents a p<0.001 by two-tailed t-test.
(d) In vitro transcription following antibody depletion and rescue using recombinant MVI (NI) (1 μM), NDP52 (10 μM) or tDAB2 (10 μM), as described in Methods *** represents a p<0.001 by two-tailed t-test.
Figure 5 Inhibition of myosin VI in estrogen linked gene expression.
(a) Immunofluorescence staining against MVI (magenta) combined with DNA staining (Cyan) in HeLa cells. Scale bar 10 \( \mu \text{m} \) in all images.
(b) Expression of estrogen receptor gene targets following siRNA knockdown of MVI (red), or TIP treatment (blue) in MCF-7 cells. Expression is plotted as a percentage of expression in mock cells. MYO6 reports on the success of the siRNA knockdown, whilst ESR1 and ACTB were used to reflect global changes in transcription. *** represents a p<0.001 by two-tailed t-test.
(c) Real-time growth of MCF-7 cells (red) and corresponding measurements following MVI siRNA knockdown (green) and mock transfection control (blue). Data represent three independent measurements and error bars show SEM. Example images at start and end time points are shown. Scale bar 300 \( \mu \text{m} \) in all images. Western-blot against DAB2 following transient transfection in to MCF-7 cells is shown in Supplementary Figure 2A.
(d) Expression of estrogen receptor target genes following transient transfections of DAB2 (magenta), DAB2\textsubscript{1-648} (blue) and DAB2\textsubscript{649-770} (red) into MCF-7 cells. Expression is plotted as a percentage of expression in non-transfected cells. MYO6, ESR1 and ACTB were used to reflect global changes in transcription. (Error bars represent SEM from 3 independent experiments. *** represents a p<0.001 by two-tailed t-test.).